$NTRA

Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 5,770 shares of Natera, Inc. (NTRA) at an average of $256.51 ($254.07–$260.49, $1.48M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market sale amount and timing under a 10b5-1 plan; it may slightly influence sentiment but does not change fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new guidance, trial result, deal, or regulatory action in the text.

03

What to watch

The price range of the sale ($254.07 to $260.49) could coincide with normal trading volatility, and the net holdings after the sale (102,973 shares) suggests continued insider exposure.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed late July, with sales executed 2026-07-27 to 2026-07-28.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $1.48M of NTRA shares via a 10b5-1 plan across two open-market trades in late July.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it provides no new operational, financial, or regulatory catalyst.

Market effects

Minimal. The disclosure is company-specific and does not introduce a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is pre-arranged under 10b5-1, the market may overreact; the transaction may not reflect negative expectations.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Chapman Steven Leonard

    CEO and President who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.